Forging a New Core, Benefiting the World, Soaring with Global Influence—Shenyang Hongqi Pharmaceutical’s 2026 Annual Work Conference Concludes Successfully

With the spring tide surging and a new chapter dawning, now is the time to row vigorously and set sail. To systematically review 2025’s performance, strategically plan for 2026’s tasks, build consensus across the organization, and pool collective strengths to propel the company’s high-quality development to a new height, Shenyang Hongqi Pharmaceutical Co., Ltd. recently held its 2026 Annual Work Conference under the theme “Forge Core Competitiveness, Benefit the World, and Soar with Momentum.”

In 2025, Shenyang Hongqi Pharmaceutical overcame numerous challenges and achieved remarkable results. Guided by the company’s strategic vision, all employees united in purpose, driving breakthrough advancements across its core business areas. Among these achievements is the globally innovative anti-tuberculosis drug, Puruini. ^® It has been successfully launched, addressing the challenges of treating drug‑resistant tuberculosis, and was included in the National Medical Insurance Catalogue in December, ushering in a new era of universal access to treatment for drug‑resistant TB. Three products—nisofenide soft capsules, among others—covering four specifications have received marketing approval, while three additional products, including bedaquiline fumarate, have completed the submission process. The overseas supply chain has been efficiently established, and Puruini ^® From approval to delivery, it took just 93 days, setting a new benchmark for “Hongqi Speed.” In the urology and andrology field, the company’s OEM business has grown steadily, positioning it among the leading suppliers of male health products, with its core offerings consistently ranking at the forefront of domestic industrial sales.

In his work report, Liu Wei, General Manager of Hongqi Pharmaceutical, provided a comprehensive review of the company’s key achievements and operational performance in 2025, while systematically outlining the priority initiatives for 2026. The report highlighted that, thanks to the concerted efforts of all colleagues, the company achieved steady progress across marketing, product development, manufacturing, and back-office support in 2025. At the same time, it acknowledged persistent challenges, including insufficient growth momentum and the need to optimize the talent structure. Looking ahead to 2026, General Manager Liu articulated clear core development goals and priority tasks: building a high‑performing marketing team; focusing on core products to accelerate reimbursement implementation and academic promotion; firmly embracing internationalization and expanding into emerging markets; pursuing a balanced approach of generic and innovative drug development with a strong emphasis on tuberculosis; broadening the R&D pipeline; deepening cost‑reduction and efficiency‑enhancing measures through lean manufacturing; strengthening the quality management system to align with international standards; empowering platform‑based operations to enhance cross‑functional collaboration; and leveraging AI technologies to drive digital transformation—thereby laying a solid foundation for the company’s sustained growth. 
 

Under the company’s new organizational structure, to accelerate the practical application of AI across the enterprise, Fan Qianwen from the Information Management Department delivered a focused presentation titled “AI Empowerment: From Visibility to Transformation.” Drawing on pharmaceutical industry case studies, she outlined AI’s application scenarios and core value across various stages of the value chain—ranging from new drug discovery to production and manufacturing—and demonstrated how AI can enhance innovation efficiency and operational capabilities, thereby injecting strong new momentum into the company’s high‑quality development.

Mr. Mou Bin, General Manager of Hongqi Pharmaceutical, commended the entire Hongqi team for their efforts in 2025 and put forward specific recommendations for the company’s development in 2026. He emphasized that the company should fully leverage the market potential of its core products, optimize its financial operating model, continuously enhance overall workforce productivity, and seize industry‑wide growth opportunities with precision. By uniting as one, focusing on concrete actions, and delivering results, the company can achieve higher‑quality, faster‑paced growth, consolidate its industry leadership, and ensure the successful implementation of its strategic objectives.

Yang Bo, Chairman of Hongqi Pharmaceutical, delivered an important address and set forth clear directives, focusing on the Group’s overall strategy, national pharmaceutical industry policies, and the sector’s development trends. He emphasized that the company must uphold its core strengths in the tuberculosis field, remain committed to enhancing innovation-driven value, actively leverage AI technologies, further deepen its international market presence, and strengthen synergies across the Group and its various platforms to establish a comprehensive closed-loop system for diagnosis and treatment. At the same time, the company should seize the significant opportunities presented by the national initiative to build a global platform for innovative medicines, integrate high-quality resources, bolster its core competitiveness, and earnestly implement the annual work theme of “Forging New Core Capabilities, Benefiting the World,” thereby driving leapfrog growth and contributing to the global effort to prevent and control tuberculosis.

In his address, Mr. Zhang Yan, Fosun Global Partner and President of Yaoyou Group, highly commended the company’s achievements in 2025 and urged all employees to focus on deepening and refining their expertise in the core field of tuberculosis, strengthen collaborative partnerships with platform‑based enterprises, leverage platform advantages to broaden growth pathways, reinforce brand building, and steadily advance the global reach of anti‑tuberculosis medicines, thereby supporting the company’s goals of professionalization and globalization.

With the blueprint in place, it is time to set sail and ride the waves; with great responsibilities on our shoulders, we must press forward with renewed vigor. The successful convening of the 2026 Work Conference has comprehensively reviewed past achievements, clarified our strategic direction, and forged a shared vision across the organization, charting a clear path and providing a solid framework for the company’s development in the year ahead. The hard work and rewards of 2025 have become the confidence that drives all members of Hongqi forward, while the opportunities and challenges of 2026 inspire each of us to strive boldly and lead the way. Looking ahead, Shenyang Hongqi Pharmaceutical will seize this conference as an opportunity to anchor itself firmly to its core objectives, deepen its presence in the global market, break new ground through innovation, and achieve lasting success through pragmatic action. Upholding our original aspirations and shouldering our mission, we will unite as one, forge ahead with determination, continuously strengthen our core competitiveness, and propel the company’s high-quality development to new heights—contributing to the global fight against tuberculosis and writing a new chapter of brilliance in 2026!